BfArM - Federal Institute for Drugs and Medical Devices

Navigation and service

Dear Doctor Letter (Rote-Hand-Brief) on Multaq® (dronedarone): Restrictions regarding the use of Multaq®

2011.09.30

Active substance: dronedarone

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has decided on restrictions as well as additional contraindications and warnings regarding the use of Multaq®.

Fachinformation zu Multaq® PDF, 267KB, File is accessible

(SPC-Summary of Product Characteristics - available in German only)

Download DHPC / Information letter , Download_VeroeffentlichtAm_EN PDF, 439KB, File is accessible